newsfilter
← Latest News
GlobeNewswire·

Royalty Pharma reports third quarter 2026 results

Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9%Net cash provided by operating activities of $686 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to